Table 3 |
|||||||
|
EBV DNA loads in various EBV-associated disease states and immunocompromised individuals. |
|||||||
|
Group |
Patient ID |
Sex/Age |
Condition |
Specimen (Positive/n Tested) |
Target |
Detectable EBV DNA Load (copies/ml) |
Clinical Notes |
|
|
|||||||
|
1. |
A. |
M/46y |
PTLD |
Plasma (5/6) |
EBNA-1 |
Day +32 - 8.0 × 102 |
MUD HSCT for AML; EBV VCA IgG positive pre-Tx; Plasma collected on Days +32, +39, +46, +60, +75 and +81 for EBV QPCR; Plasma EBV (qualitative) PCR positive on Days +75, +78 and +81; Treatment with Foscarnet and Rituximab after Day +75; Died of pneumonia on Day +88 |
|
Day +46 - 1.0 × 103 |
|||||||
|
Day +60 - 8.8 × 103 |
|||||||
|
Day +75 - 1.1 × 106 |
|||||||
|
Day +81 - 2.3 × 105 |
|||||||
|
CSF (2/2) |
EBNA-1 |
Day +75 - 1.3 × 106 |
CSF collected on Days +75 and +78 |
||||
|
Day +78 - 2.7 × 106 |
|||||||
|
B. |
M/42y |
PTLD |
Whole Blood (1/5) |
EBNA-1 |
Day +95 - 2.0 × 107 |
MUD HSCT for AML; Plasma EBV (qualitative) PCR positive Day +96; Plasma collected on Day +95 for EBV QPCR; Died on Day +99 due to multi-organ failure |
|
|
C. |
F/59y |
PTLD |
Plasma (3/6) |
EBNA-1 |
Day +45 - 2.2 × 105 |
MUD HSCT for AML; CMV reactivation on Day +44, Treatment with Foscarnet and ganciclovir on Day +52; Plasma collected Days +38, +40, +45, +52 and +59; Died on Day +66; EBV VCA IgG positive, HHV6 IgG positive and CMV IgG positive pre-Tx |
|
|
Day +52 - 9.6 × 103 |
|||||||
|
Day +59 - 3.0 × 105 |
|||||||
|
Whole Blood (1/8) |
EBNA-1 |
Day +46 - 6.6 × 104 |
EDTA collected Days +3, +5, +10, +17, +26, +31, +33, +46 |
||||
|
D. |
M/48y |
PTLD |
Plasma (4/6) |
EBNA-1 |
Day +40 - 3.4 × 103 |
MUD HSCT for AML; EBV VCA IgG positive pre-Tx; Plasma collected Days +28, +33, +40, +47, +54, +61; Plasma EBV (qualitative) PCR negative on Day +62; Died Day +72 of multi-organ failure |
|
|
Day +47 - 3.6 × 104 |
|||||||
|
Day +54 - 3.4 × 106 |
|||||||
|
Day +61 - 6.3 × 106 |
|||||||
|
Whole Blood (2/2) |
EBNA-1 |
Day +62 - 1.3 × 108 |
EDTA collected Days +62 and +63. |
||||
|
Day +63 - 1.8 × 107 |
|||||||
|
E. |
F/57y |
PTLD |
Whole Blood (1/5) |
EBNA-1 |
9.5 × 104 |
No serology results available however clinical notes indicate EBV reactivation; Plasma EBV (qualitative) PCR positive 9-16 days after VL testing done; negative at 1-7 months thereafter. |
|
|
2. |
F. |
Unknown |
IM |
Plasma (1/1) |
EBNA-1 |
3.7 × 104 |
EBV VCA IgM positive |
|
BHRF-1 |
1.6 × 104 |
||||||
|
G. |
Unknown |
IM |
Plasma (0/1) |
EBNA-1 |
0 |
EBV VCA IgM positive |
|
|
BHRF-1 |
0 |
||||||
|
H. |
Unknown |
IM |
Plasma (1/1) |
EBNA-1 |
7.6 × 103 |
EBV VCA IgM positive |
|
|
BHRF-1 |
1.5 × 103 |
||||||
|
I. |
Unknown |
IM |
Plasma (1/1) |
EBNA-1 |
2.3 × 103 |
EBV VCA IgM positive |
|
|
BHRF-1 |
8.7 × 104 |
||||||
|
J. |
M/17y |
IM |
Whole Blood (1/1) |
EBNA-1 |
1.0 × 105 |
EBV VCA IgM positive |
|
|
BHRF-1 |
1.8 × 103 |
||||||
|
K. |
F/19y |
IM |
Whole Blood (1/1) |
EBNA-1 |
2.2 103 |
EBV VCA IgM positive |
|
|
BHRF-1 |
5.6 × 104 |
||||||
|
L. |
F/53y |
IM |
Whole Blood (1/1) |
EBNA-1 |
2.0 × 105 |
EBV VCA IgM positive; acute glandular fever |
|
|
BHRF-1 |
1.8 × 104 |
||||||
|
3. |
M. |
M/36y |
EBVAHS |
Whole Blood (1/1) |
EBNA-1 |
7.5 × 104 |
EBV (qualitative) PCR positive; died of EBVAHS |
|
BHRF-1 |
1.1 × 105 |
||||||
|
4. |
N. |
Unknown |
HIV |
Plasma (1/1) |
EBNA-1 |
0 |
HIV plasma VL 324, 000 RNA copies/ml |
|
BHRF-1 |
1.0 × 103 |
||||||
|
O. |
Unknown |
HIV |
Plasma (0/1) |
EBNA-1, |
0 |
HIV plasma VL 13, 000 RNA copies/ml |
|
|
BHRF-1 |
0 |
||||||
|
P. |
Unknown |
HIV |
Plasma (0/1) |
EBNA-1, |
0 |
HIV plasma VL 26, 800 RNA copies/ml |
|
|
BHRF-1 |
0 |
||||||
|
Q. |
Unknown |
HIV |
Plasma (0/1) |
EBNA-1, |
0 |
HIV plasma VL 21, 300 RNA copies/ml |
|
|
BHRF-1 |
0 |
||||||
|
R. |
Unknown |
HIV |
Plasma (0/1) |
EBNA-1, |
0 |
HIV plasma VL 12, 700 RNA copies/ml |
|
|
BHRF-1 |
0 |
||||||
|
S. |
Unknown |
HIV |
Plasma (0/1) |
EBNA-1, |
0 |
HIV plasma VL 1, 040, 000 RNA copies/ml |
|
|
BHRF-1 |
0 |
||||||
|
T. |
Unknown |
HIV |
Plasma (0/1) |
EBNA-1, |
0 |
HIV plasma VL 17, 700 RNA copies/ml |
|
|
BHRF-1 |
0 |
||||||
|
U. |
Unknown |
HIV |
Plasma (0/1) |
EBNA-1, |
0 |
HIV plasma VL 47, 500 RNA copies/ml |
|
|
BHRF-1 |
0 |
||||||
|
V. |
Unknown |
HIV |
Plasma (1/1) |
EBNA-1 |
5.6 × 103 |
HIV plasma VL 16, 400 RNA copies/ml |
|
|
BHRF-1 |
3.0 × 103 |
||||||
|
W. |
Unknown |
HIV |
PBMC (1/1) |
EBNA-1 |
< 2.0 × 102 |
HIV PBMC VL 12, 800 RNA copies/ml |
|
|
BHRF-1 |
< 2.0 × 102 |
||||||
|
X. |
Unknown |
HIV |
PBMC (1/1) |
EBNA-1 |
< 2.0 × 102 |
HIV PBMC VL 12, 700 RNA copies/ml |
|
|
BHRF-1 |
0 |
||||||
|
Y. |
Unknown |
HIV |
PBMC (0/1) |
EBNA-1, |
0 |
HIV PBMC VL 118, 000 RNA copies/ml |
|
|
BHRF-1 |
|||||||
|
|
|||||||
|
Abbreviations: Y, years; Group 1 (PTLD), post-transplant lymphoproliferative disease; Group 2 (IM), infectious mononucleosis; Group 3 (EBVAHS), Epstein-Barr virus associated-haemophagocytic syndrome; Group 4 (HIV infection), human immunodeficiency virus; EDTA, ethylenediaminetetraacetic acid; CSF, cerebrospinal fluid; PBMC, peripheral blood mononuclear cells; EBNA-1, Epstein-Barr virus nuclear antigen-1; BHRF-1, BamHI fragment H rightward open reading frame-1; ml, millilitres; Bold lettering indicates Day QPCR positive post-transplant; AML, acute myeloid leukaemia; MUD; matched unrelated donor; HSCT, haematopoietic stem cell transplantation; CMV, cytomegalovirus; VCA, viral capsid antigen; Ig, immunoglobulins; EA-D, early antigen-diffuse; EA-R, early antigen-restricted; VL, viral load |
|||||||
|
Lay et al. Virology Journal 2010 7:252 doi:10.1186/1743-422X-7-252 |
|||||||
